Orsiro Hybrid Drug-Eluting Stent: Phase IV started

Biotronik began the open-label European Phase IV BIOFLOW-II trial in about 440 patients to compare its Orsiro Hybrid Drug-Eluting Stent vs. Xience Prime from Abbott Laboratories (NYSE:ABT, Abbott Pa...